Welcome to Zydus Pharmaceuticals
Zydus Warfarin Sodium is a generic prescription medication that has been approved by the FDA and is bioequivalent to Coumadin®*. Warfarin, an anticoagulant, is a drug used to reduce the risk of abnormal or dangerous blood clots.
The information provided within this website is a helpful resource to patients, caregivers, pharmacists, and healthcare providers alike to help understand and manage anticoagulation therapy.
This information is an additional resource and does not replace the advice of your healthcare provider. Please see complete prescribing information for additional information.
|WARNING: BLEEDING RISK
Warfarin sodium can cause major
or fatal bleeding. Bleeding is more likely to occur during the starting
period and with a higher dose (resulting in a higher INR). Risk factors
for bleeding include high intensity of anticoagulation (INR >4.0), age
≥65, highly variable INRs, history of gastrointestinal bleeding,
hypertension, cerebrovascular disease, serious heart disease, anemia,
malignancy, trauma, renal insufficiency, concomitant drugs (see
PRECAUTIONS in full prescribing information), and long duration of
warfarin therapy. Regular monitoring of INR should be performed on all
treated patients. Those at high risk of bleeding may benefit from more
frequent INR monitoring, careful dose adjustment to desired INR, and a
shorter duration of therapy. Patients should be instructed about
prevention measures to minimize risk of bleeding and to report
immediately to physicians signs and symptoms of bleeding (see
PRECAUTIONS in full prescribing information).
Anticoagulation is contraindicated in any localized or general
physical condition or personal circumstance in which the hazard of
hemorrhage might be greater that the potential clinical benefits of
anticoagulation, such as: in women who are or may become pregnant,
because Warfarin may cause fatal hemorrhage to the fetus and reports of
birth malformations; recent or contemplated surgery of the central
nervous system, eye or traumatic surgery with large open surfaces;
bleeding tendencies associated with active ulceration; threatened
abortion, inadequate laboratory facilities; unsupervised patients;